Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients With Schizophrenia

NCT01412060 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT01412060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01412060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients With Schizophrenia
Lead sponsor
Forest Laboratories
Phase
Phase 3
Overall status
Completed
Start date
September 27, 2011
Completion date
September 3, 2014
Enrollment
765 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia